Q (sonnet): Are TP53 mutations clinically actionable?

═ answer (success)
I can help you explore TP53 mutation data in cBioPortal, but I can't make clinical actionability determinations — that requires clinical judgment and resources like OncoKB's therapeutic actionability levels, which go beyond mutation frequency data.

**What I can do:**
- Show you TP53 mutation frequency and distribution across specific cancer types/studies
- Show driver annotation status *if it's present in the database* (I won't claim "oncogenic" or "actionable" without confirming this from queried data)
- Link you to cBioPortal's Mutations tab, which displays OncoKB annotation badges (including therapeutic actionability levels) directly in the UI when available

**Important distinction:** TP53 is one of the most frequently mutated genes across nearly all cancer types, but high mutation frequency ≠ clinical actionability. Unlike genes such as EGFR, BRAF, or KRAS (which have FDA-approved targeted therapies tied to specific mutations), TP53 mutations generally lack approved targeted therapies in routine clinical practice — but this is a clinical/regulatory fact, not something I should assert without pointing you to authoritative sources (e.g., OncoKB, FDA labels, NCCN guidelines).

> I can help you visualize the relevant data in cBioPortal, but this is for research purposes only. I cannot offer clinical advice or actionability determinations. For authoritative actionability annotations, please consult OncoKB directly or your institutional molecular tumor board.

Would you like me to:
1. Pull TP53 mutation frequency for a specific cancer type/study, and link you to the Mutations tab where OncoKB annotations (if available) are displayed?
2. Something else specific about TP53 in a particular cohort?